R&D News | pharmaphorum

News

Cosmo Feilding Mellen, Beckley Psytech’s chief executive

Beckley builds case for its psychedelic depression therapy

Beckley Psytech, just months away from a readout of a phase 2b trial of its psychedelic therapy for treatment-resistant depression (TRD), has built anticipation with new d

News

Blackstone bankrolls Moderna’s flu shot with $750m

Moderna’s efforts to develop a range of mRNA vaccines for influenza have been bolstered with funding of up to $750 million from investment firm Blackstone Life Sciences.

News

Brainomix AI shows its worth in AZ pulmonary fibrosis trial

Artificial intelligence-powered software developed by Brainomix has been shown to identify patients with idiopathic pulmonary fibrosis (IPF) at risk of decline in a clinic

News

Nanoscope preps filing for retinitis pigmentosa gene therapy

Nanoscope Therapeutics is on the brink of filing for FDA approval of what could be the first gene therapy for incurable eye disease retinitis pigmentosa (RP) that can be u

News

Nuvation Bio nears commercial stage with AnHeart buy

Nuvation Bio has accelerated its development into a commercial-stage biotech with a deal to acquire AnHeart Therapeutics and its late-stage lung cancer therapy taletrectin

News

Ex-BioMarin CEO Bienaimé re-emerges at Owkin

Just four months after ending an 18-year stint as chief executive of BioMarin, Jean-Jacques Bienaimé, has been named chairman of Owkin, a specialist in applying artificial

Beckley builds case for its psychedelic depression therapy

Blackstone bankrolls Moderna’s flu shot with $750m

Brainomix AI shows its worth in AZ pulmonary fibrosis trial

Nanoscope preps filing for retinitis pigmentosa gene therapy

Nuvation Bio nears commercial stage with AnHeart buy

Ex-BioMarin CEO Bienaimé re-emerges at Owkin

UK seeks views on indefinite CE marks for medical devices

How to meet your physicians where they are online

News

Editor's Picks